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Abstract
Background: A genomic region on chromosome 9p21 has been identified as closely associated with increased 
susceptibility to coronary artery disease (CAD) and to type 2 diabetes (T2D) although the evidence suggests that the 
genetic variants within chromosome 9p21 that contribute to CAD are different from those that contribute to T2D.
We carried out an association case-control study in an Italian population to test the association between two single
nucleotide polymorphisms (SNPs) on the 9p21 locus, rs2891168 and rs10811661, previously reported by the
PROCARDIS study, and respectively myocardial infarction (MI) and T2D. Our aim was to confirm the previous findings
on a larger sample and to verify the independence of their susceptibility effects: rs2891168 associated with MI but
not with T2D and rs10811661 associated with T2D but not with MI.
Methods: Genomic DNA samples of 2407 Italians with T2D (602 patients), who had had a recent MI (600), or had both 
diseases (600) and healthy controls (605) were genotyped for the two SNPs. The genotypes were determined by allelic 
discrimination using a fluorescent-based TaqMan assay.
Results: SNP rs2891168 was associated with MI, but not with T2D and the G-allele odds ratio (OR) was 1.20 (95% CI 
1.02-1.41); SNP rs10811661 was associated with T2D, but not with MI, and the T-allele OR was 1.27 (95% CI 1.04-1.55). 
ORs estimates from the present study and the PROCARDIS study were pooled and confirmed the previous findings, 
with greater precision.
Conclusions: Our replication study showed that rs2891168 and rs10811661 are independently associated respectively 
with MI and T2D in an Italian population. Pooling our results with those reported by the PROCARDIS group, we also 
obtained a significant result of association with diabetes for rs10811661 in the European population.
Background
Recent genome-wide association studies (GWAS) have
identified a genomic region on chromosome 9, approxi-
mately 22 million base pairs from the 9p telomere, closely
associated with increased susceptibility to coronary
artery disease (CAD) [1-4]. This region maps near two
well-characterized tumor suppressor genes, CDKN2A
and CDKN2B, encoding respectively proteins p16 INK4a
and p15 INK4b, involved in the regulation of cell prolifera-
tion, cell aging and apoptosis [5], mechanisms that have a
critical role in atherosclerosis [6]. Protein p16INK4a inhib-
its cyclin-dependent kinase 4(CDK4) and is a strong reg-
ulator of pancreatic beta cell replication [7-9]. The same
region has also recently been associated with abdominal
aortic and intracranial aneurysms [10].
Three recent studies found increased susceptibility to
type 2 diabetes (T2D) for carriers of single nucleotide
polymorphism (SNP) rs10811661 mapping the chromo-
some 9p21 [11-13]. The same allelic variant showed the
strongest and most consistent association in a meta-anal-
ysis of T2D GWAS [12] (Table 1).
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T2D has long been recognized as a major risk factor for
atherosclerosis, and therefore for CAD, although their
temporal and etiological relationships are not clear: CAD
usually follows diabetes mellitus, though it can some-
times precede it. Doria et al. showed that the CAD risk
associated with a 9p21 variant was higher in type 2 dia-
betic patients with poor glycemic control [14].
The presence of several different SNPs within chromo-
some 9p21 associated with such tightly related diseases
prompted us to investigate a shared susceptibility variant,
although the evidence suggests that different genetic vari-
ants within chromosome 9p21 contribute to CAD and
T2D. The PROCARDIS Consortium's results showed that
two different SNPs, rs2891168 and rs10811661, both in
the 9p21 region although rs2891168 belongs to the CAD-
associated locus while rs10811661 is localized outside,
are associated with CAD and diabetes respectively, and
the two susceptibility effects are independent [15]. How-
ever, there are several reasons why the PROCARDIS
results cannot be regarded as conclusive. Most impor-
tantly, the study was not conceived, and did not have suf-
ficient statistical power to answer this question as the
number of diabetic patients without CAD was quite
small. To confirm and replicate these results, a larger
sample was deemed necessary.
Therefore we carried out a case-control association
study in a population of Italian patients with T2D only,
myocardial infarction (MI) only, or both diseases, to test
the susceptibility effects of rs2891168 and rs10811661.
Our aim was to confirm previous findings on a larger
sample and to verify whether the effects of these two
SNPs on susceptibility to MI and T2D were actually inde-
pendent: rs2891168 associated with MI but not with T2D
and rs10811661 associated with T2D but not with MI.
Methods
Study population
The study population consists of 2407 unrelated Italians,
1739 men and 668 women.
We enrolled all the patients (602) with T2D who had a
blood sample available among those in the IGLOO
cohort study (Impaired Glucose intolerance & Long-term
Outcomes Observational Study) [16]. The other case
groups of 600 MI only and 600 MI&T2D were selected at
random from the GISSI-Prevenzione study (GISSI-P)
[17]. GISSI-P and IGLOO are both multicentre Italian
studies approved by the local ethics committees of the
participating hospitals (see references 16,17 for the com-
plete list). Written informed consent to participate in the
study, including blood sampling, was obtained for each
subject.
The characteristics of the participants have been
described previously [16,17]. In brief, GISSI-P patients
were selected on the basis of a clinical diagnosis of recent
(< = 3 months) MI, with no limits of age and distinction
of sex. The IGLOO population comprised men and
women aged between 55 and 75 years, with no history of
cardiovascular events such as angina and MI but with one
or more cardiovascular risk factors. All patients were
referred to a diabetes outpatient clinic for an oral glucose
Table 1: Association of rs2891168 with coronary artery disease (CAD) and rs10811661 with type 2 diabetes (T2D) in 
different populations.
SNP Risk 
allele
Risk allele 
frequency
Study population 
(no. cases)
OR§
(95% CI)
P-value Genetic 
approach
Ref.*
rs2891168 G 0.59 Europeans (4251) 1.29
(1.20-1.38)
6 × 10-13 Case-
control 
study
[15]
rs10811661 T 0.85 Finns (2314) 1.20
(1.07-1.36)
2.2 × 10-3 GWAS [11]
0.82 UK (5681) 1.19
(1.11-1.28)
4.9 × 10-7 Meta-
analysis of 
GWAS
[12]
0.83 Scandinavians Poles, 
US (6529)
1.20
(1.12-1.28)
5.4 × 10-8 GWAS [13]
0.86 Dutch (9132) 1.30
(1.16-1.47)
1 × 10-5 Validation 
of GWAS
[24]
0.56 Chinese Hans (1302) 1.31
(1.12-1.54)
1 × 10-3 Replication 
study
[25]
* Ref: reference
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tolerance test, with determination of venous plasma glu-
cose, fasting and 2 hours after the ingestion of 75 g glu-
cose. Those recruited for the present study all had T2D.
Major details of the study design, eligibility criteria, and
IGLOO and GISSI-P results are reported elsewhere
[16,17].
A group of 605 unmatched Italian controls was
recruited among blood donors listed with AVIS (the Ital-
ian blood donors' association). Donors have regular rou-
tine check-ups of their state of health. The following
inclusion criteria were used: age < = 65 years, no history
of diabetes, no CAD and no first-degree relatives with
CAD. Therefore, controls were expected to be at a very
low risk of cardiovascular events and T2D.
Patients in the T2D group were older but the other
groups were close in age (Table 2).
The studied population can be considered representa-
tive of Italians from all regions and homogeneous in
terms of genetic constitution since subjects derived from
the previous studies and controls are all white Italians, of
European ancestry, without the possibility to isolate any
subpopulations based on ethnicity, differences in disease
prevalence and/or risk allele frequencies among groups.
SNP selection
Two previously reported susceptibility SNPs on chromo-
some 9p21 [15] (rs2891168 and rs10811661) were
selected for genotyping in the present study and are
described in Table 3.
We selected these genetic variants in view of our aim to
replicate the PROCARDIS investigators' analysis who
selected these out of 11 literature SNPs initially consid-
ered. Using an entry P-value threshold of 0.01, SNP
rs2891168 was selected as it showed the strongest associ-
ation with CAD (P = 6 × 10-13) in their population, with a
per-G allele odds ratio (OR) of 1.29 (95% CI 1.20-1.38)
[15]. rs10811661 has been identified through the recent
GWAS [11-13] and showed the most consistent associa-
tion in a meta-analysis of T2D GWAS [12].
Genotyping
DNA was extracted from frozen EDTA-whole blood
using a salting-out procedure [18]. All polymerase chain
reactions (PCRs) were done in a volume of 5 μl contain-
ing TaqMan universal PCR Master Mix, specific TaqMan®
SNP Genotyping Assays, purchased from Applied Biosys-
tems (ABI) (Foster City, CA, USA), and 10 ng of genomic
DNA, according to the manufacturer's instructions. The
7900 Real-Time PCR System (ABI) was used for SNP
genotyping. The fluorescent data files for each plate were
analyzed using Sequence Detection System version 3.2
(ABI). To ensure the quality of automatic allele calling, all
samples were analyzed in two replicates and the concor-
dance rate was 100%. No genotype data were missing.
Statistical analysis
Hardy-Weinberg (HW) equilibrium was tested using the
genhw STATA package. Additive and non-additive effects
were modeled by comparing an additive model in terms
of logit, i.e. a model of allelic association, and a model of
genotype association, by the likelihood ratio test. Associ-
ation analyses were done between the presence of the
SNP rs2891168 G-allele and the SNP rs10811661 T-allele
and MI, T2D and MI&T2D case groups using uncondi-
tional multinomial logistic regression. ORs and 95% con-
fidence intervals (CI) were calculated comparing case
groups with the controls. Homogeneity of risks among
case groups was assessed using a Wald test with one
degree of freedom [19]. ORs estimates in the present
study and in the PROCARDIS study [15] were pooled
using a fixed-effects model.
The QUANTO software was used for power calculation
on pooled data [20] and STATA 9.0 for the statistical
analysis.
Results
Both SNPs were in HW equilibrium among controls (p ≥
0.3). Risk allele frequencies in the study population were
in agreement with published data [15]. Single marker
Table 2: Main details of the study groups: sample size, sex and age.
group No. of subjects Women
(%)
Age (yrs)
mean (SD*)
T2D§ 602 43.2 62.4 (7.3)
MI† 600 20.8 57.5 (6.5)
MI&T2D 600 28.2 58.2 (7.5)
Controls 605 18.8 56.6 (6.5)
Total 2407 27.7 58.7 (7.3)
*SD: standard deviation;
§T2D: type 2 diabetes;
†MI: myocardial infarction.Gori et al. BMC Medical Genetics 2010, 11:60
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tests supported an additive genetic model on the logit
scale (p > 0.10), consistent with an allelic association
model.
In unconditional multinomial logistic regression mod-
eling additive genetic effects, SNP rs2891168 was associ-
ated with MI (p = 0.03) and not with T2D, and the G-
allele OR was 1.20 (95%CI 1.02-1.41). SNP rs10811661
was associated with T2D (p = 0.02) and not with MI, and
the T-allele OR was 1.27 (95%CI 1.04-1.55). ORs and 95%
CIs calculated by comparing cases (T2D, MI, MI&T2D)
with controls are reported in Figure 1.
Comparing the homogeneity of genetic risks in the
diagnostic groups, the rs2891168 G-allele OR of the
MI&T2D group was significantly different from the T2D
group (p = 0.04), while the rs10811661 T-allele OR of the
MI&T2D group was significantly different from the MI
group (p = 0.005). These results indicated that SNP
rs2891168 was associated with MI, SNP rs10811661 with
T2D, and confirmed that the two susceptibility variants
are independently associated with the two separate dis-
eases in our Italian population.
Pooled ORs were calculated using the PROCARDIS
results and are reported in Figure 2.
SNP rs2891168 was confirmed as associated with CAD
(p < 0.0001) with a G-allele OR of 1.28 (95% CI 1.20-1.36),
and SNP rs10811661 was associated with T2D (p = 0.04)
with a T-allele OR of 1.19 (95%CI 1.01-1.41).
Given these allele frequencies and assuming a 5% prev-
alence of diabetes [21], and a type 1 error rate of 0.05, a
post-hoc power calculation indicated that our sample of
Italian T2D cases (602) pooled with the PROCARDIS
diabetics (156) had 80% power to detect an association in
terms of an OR of 1.30 between the rs10811661 T variant
and diabetes.
Discussion
Estimates of genetic effect size from genome-wide
screens are frequently biased [22] and more precise esti-
mates can be obtained in independent replication
cohorts. In the PROCARDIS study the magnitude of the
susceptibility effect for CAD (OR = 1.29; 95% CI: 1.20-
1.38) was very similar to previous GWAS [15]. The main
finding of the present study is therefore its ability to repli-
cate the analysis done in the European PROCARDIS pop-
ulation on an independent cohort of Italians, with
comparable inclusion criteria.
The ORs for the susceptibility effects of rs2891168 and
rs10811661 on MI and T2D (Figure 1) are in line with
previous evidence that these genetic signals are indepen-
dently associated with the two diseases. CAD susceptibil-
ity conferred by rs2891168 was strongly proved in the
PROCARDIS population. Its susceptibility effect on MI
(OR = 1.20; 95%CI 1.02-1.41) in the Italian population is
less strong. However, PROCARDIS patients had docu-
mented diagnoses of MI, symptomatic acute coronary
syndrome, intervention for coronary revascularization, or
chronic stable angina, the four major diagnostic out-
comes [23] for a heterogeneous disease like CAD. There
is considerable overlap between these outcomes, yet their
underlying pathophysiology differs significantly. In this
respect the Italian patients considered in the present
Figure 1 rs2891168 association with MI and rs10811661 with T2D 
in the Italian sample. Solid squares are centered on the ORs and 
scaled in proportion to the inverse variance of the estimates with 95% 
CI (horizontal bar) for groups, comparing MI with or without a clinical 
history of diabetes. The reference group is non-MI, non-diabetics (605). 
The number of individuals in each group (n) is shown.
Table 3: Characteristics of the SNPs rs2891168 and rs10811661 in the study population.
SNP Position
(bp)
HWE* χ2 test
p-value
Risk allele Risk allele frequency
rs2891168 21921500 0.81 G 0.59
rs10811661 22124094 0.80 T 0.80
* HWE: Hardy-Weinberg EquilibriumGori et al. BMC Medical Genetics 2010, 11:60
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study are more homogeneous: they are surely CAD
patients but all had a clinically diagnosed MI.
By contrast, there was no conclusive evidence of an
association between rs10811661 and diabetes risk in the
PROCARDIS analysis, probably because the diabetic
group was too small to produce reliable results. A limita-
tion the PROCARDIS authors mentioned is that the dia-
betic population included individuals with both types 1
and 2 diabetes without the possibility to distinguish them.
In the present study the diabetic patients all had T2D, so
it is important to note that rs10811661 is a genetic risk
factor for T2D in the Italian population (OR = 1.27;
95%CI 1.04-1.55), as has been reported so far for several
European populations [11,12,24] and for the Han Chinese
[25], with an average associated OR of 1.25 for the risk
allele variant, although the East Asians have a lower prev-
alence of diabetes and different risk allele frequency from
Europeans [26].
Pooling our data and the PROCARDIS data, thus
increasing the sample size, we confirmed the association
of rs2891168 with CAD and, most importantly, we found
a significant association with diabetes for rs10811661 in
the European population. Consistent results in the two
studies and the greater precision of the pooled estimates
support the association and confirm the hypothesis on
this larger sample.
According to the PROCARDIS data analysis [15], the
association model between SNPs and case groups was
not adjusted for confounders. Actually they tested
whether the susceptibility between CAD and rs2891168
changed significantly in subgroups of CAD patients (reg-
ular smoker, sex, age, obesity, diabetes and hypertension);
none of these potential confounders affected the associa-
tions. In order to pool our data with those of the PRO-
CARDIS study we used the same statistical approach.
Moreover, available covariates are intermediate pheno-
types for the outcome of interest and their inclusion as
exposures may reduce the effect of overlapping genetic
factors.
Sometimes replication studies fail to confirm initial
findings because of substantial differences between study
populations and population specificity that may consist
in differences in linkage disequilibrium (LD) block, popu-
lation-specific interactions between genes, and epige-
netic modifications. Therefore, the fact that the present
study replicated a significant evidence of association in an
independent cohort of Italians helps clarify the genetic
component's contribution in different populations for
multifactorial diseases like MI and T2D, so it can be con-
sidered a step forward to producing trustworthy results.
Despite the many GWAS done in the last few years, and
the many genetic factors identified, the precise genetic
background to complex human diseases such as CAD and
T2D is still not clear. There is strong evidence of associa-
tions between common variants within chromosome
9p21 and the risk of CAD and T2D, but so far the biologi-
cal function of most of them and how they are linked with
the clinical phenotype is still not known. Further physio-
logical and functional studies are needed to clarify the
molecular mechanisms and pathways underlying the
associations with CAD or T2D. These could help identify
biological targets for the prevention or treatment of these
common diseases and may establish whether certain
allelic variants have any effects on other genes, for
instance CDKN2A and CDKN2B, since they are the clos-
est to the 9p21 CAD and T2D loci.
Helgadottir et al. reported that chromosome 9p21 is
associated not only with MI but also with an increased
risk to develop abdominal aortic and intracranial aneu-
rysms [10]. Björck et al. also found an association
between genetic variation on chromosome 9p21.3 and
arterial stiffness [27]. These findings suggest that this
locus is not directly and/or exclusively involved in the
pathogenesis of MI but may play an important role in the
integrity of the vessel wall, thus influencing a broad range
of cardiovascular disorders.
Conclusions
In summary, we report that SNPs rs2891168 and
rs10811661 are independently associated respectively
Figure 2 rs2891168 association with CAD and rs10811661 with 
diabetes: pooled estimates with PROCARDIS data. Solid squares 
are centered on the ORs and scaled in proportion to the inverse vari-
ance of the estimates with 95% CI (horizontal bar) for groups compar-
ing CAD with or without a clinical history of diabetes. The reference 
group is non-CAD, non-diabetics (4910). The number of pooled indi-
viduals in each group (n) is shown.Gori et al. BMC Medical Genetics 2010, 11:60
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with MI and T2D in an Italian population. Combining
our results with those reported by the PROCARDIS
group, we found a significant association with diabetes
for rs10811661 in the European population.
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